INTRODUCTION
============

CS (chondroitin sulfate) is a type of GAG (glycosaminoglycan), which are present in the extracellular matrices and on the surface of many cell types \[[@B1]\]. Similar to other GAGs, CS is attached to a serine residue of the core protein to form the CSPG \[CS PG (proteoglycan)\] \[[@B1]\]. After the formation of a common linkage region (GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-*O*-Ser) between sugar chains and the core protein, repeating disaccharide units of GalNAc (*N*-acetylgalactosamine) and GlcUA (glucuronic acid) residues with interspersed sulfate residues are synthesized \[[@B1]\]. Thus biosynthesis of a CS-specific polysaccharide chain is initiated by the transfer of a GalNAc residue to the tetrasaccharide linker, followed by the addition of GlcUA and GalNAc residues in reiterative chain elongation steps.

There are six glycosyltransferases known to be involved in CS synthesis \[[@B2]--[@B10]\]. Among them, CSGalNAcT1 (CS N-acetylgalactosaminyltransferase-1) and CSGalNAcT2 each have one glycosyltransferase domain, exhibit GalNAc transfer activity in both the initiation and elongation processes, and are thought to be responsible for the addition of the first GalNAc residue to the tetrasaccharide chain \[[@B4]--[@B7]\]. Although each of the six enzymes has been characterized biochemically in *in vitro* studies, the mechanism of *in vivo* CS biosynthesis, including roles for each glycosyltransferase, is poorly understood. Since cartilage contains the largest amount of CS of all body tissues, chondrocytes efficiently synthesize CS chains \[[@B11],[@B12]\]. CS in cartilage is selectively linked to aggrecan, which can possess more than 100 CS chains; these CSPGs subsequently form multimolecular aggregates through interaction with hyaluronate and linker proteins \[[@B13]\]. CSGalNAcT1 is highly expressed in the developing cartilage, and this enzyme is thought to play a crucial role in CS biosynthesis on the basis of a study using cell lines \[[@B14]\]. Moreover, CSGalNAcT1 is thought to have important roles in chondrogenesis at early developmental stages \[[@B14]\].

To investigate the physiological role of CSGalNAcT1 in CS biosynthesis, we produced *CSGalNAcT1*-null mice and analysed the morphology and biochemistry of developing cartilage in these mutants. The mice were viable and fertile; however, the amount of CS was reduced by half relative to the amount in wild-type controls, and the null mice showed an abnormal profile of GAG chains in the biochemical analysis of CS. The thickness of the epiphyseal cartilage layer was decreased by 25% at E (embryonic day) 18.5. Moreover, the hindlimb and the body were also shorter. Taken together, our data suggest that CSGalNAcT1 plays a role in CS synthesis in the cartilage during embryonic development.

EXPERIMENTAL
============

Materials
---------

*Proteus vulgaris* chondroitinase ABC (EC 4.2.2.4) was purchased from Seikagaku. The Superdex™ 200 10/300 GL column was obtained from Amersham Pharmacia Biotech.

Generation of *CSGalNAcT1*-null mice
------------------------------------

All animal experiments were carried out in accordance with the guidelines laid down by the animal welfare committees of Niigata University. The *CSGalNAcT1*-null mice were produced by homologous recombination using a new ES (embryonic stem) cell line, RENKA, which we developed from the *C57BL/6N* strain \[[@B15]\].

The mouse *CSGalNAcT1* gene (chondroitin 4-sulfotransferase-1) was identified by homology with the human *CSGalNAcT1* gene (GenBank® accesion number NM_172753) \[encoding 530 amino acids; 89% identity and 92% similarity to human EC 2.4.1.174 (NM_001130518)\]. A 1.8-kb DNA fragment, which carried the 34-bp loxP sequence and Pgk-1 promoter-driven neomycin phosphotransferase gene (neo) flanked by two Flp recognition target (frt) sites \[[@B16]\], was inserted into a site 372 bp upstream of exon 7. The 34-bp loxP sequence was inserted into a site 249 bp downstream of exon 6. The targeting vector, ptv *CSGALNACT1*-flox, contained exon 7 of the *CSGalNAcT1* gene flanked by loxP sequences, genomic sequences from 3.4 kb upstream and 7.1 kb downstream of exon 6, and a 4.3 kb pMC1DTpA vector \[[@B17]\].

ES cells were cultured on mitomycin C-treated neomycin-resistant fibroblasts in DMEM (Dulbecco\'s modified Eagle\'s medium; high glucose; Invitrogen) supplemented with 17.7% ES-cell-qualified fetal bovine serum (Invitrogen), 88.4 μM non-essential amino acids (Invitrogen), 884 μM sodium pyruvate (Sigma), 88.4 μM 2-mercaptoethanol (Sigma) and 884 units/ml of murine leukaemia inhibitory factor (ESGRO; Chemicon International). Linearized targeting vector was electroporated into RENKA cells, and G-418 (175 μg/ml)-resistant clones were picked. Recombinant clones were identified by Southern blot hybridization analysis. Recombinant ES cells were injected into eight-cell-stage embryos of the CD-1 mouse strain. The embryos were cultured to blastocysts and transferred to the uterus of a pseudopregnant CD-1 mouse. Resulting chimaeric mice were mated to C57BL/6N mice, and heterozygous offspring \[*CSGalNAcT1*^*+/floxneo*^\] were mated to telencephalin-*cre* mice \[[@B18],[@B19]\]. The resulting heterozygous (*CSGalNAcT1*^+/−^; *Cre*^+/−^) mice were mated with C57BL/6N mice and the mice without the *Cre* gene were selected. Homozygous mutant mice and control mice were obtained by crossing heterozygous pairs.

Genotypes of the *CSGalNAcT1*^*+/floxneo*^ mice and *CSGalNAcT1*^+/−^ mice were identified by Southern blot hybridization analysis. Elimination of the *Cre* gene was confirmed by PCR using 5′-GCCTGCATTACCGGTCGATGCAACG-3′ (CreP1) and 5′-GCCCGGACCGACGATGAAGCATGTT-3′ (CreP2) \[[@B20]\] with internal control primers 5′-CCAGCTCCAGGGATCTAACA-3′ and 5′-ATTAAGGGCCAGCTCATTCC-3′ (glutamate receptor GluN2A subunit). Routine genotyping of *CSGalNAcT1*^+/−^ animals was conducted by PCR using the primers 5′-CCAGCTCCAGGGATCTAACA-3′ and 5′-TGGTTTCCTCTAGCCATTGC-3′.

Derivatization of CS from articular cartilage using a fluorophore, 2-AB (2-aminobenzamide)
------------------------------------------------------------------------------------------

Articular cartilage CSPG from E18.5 embryos was extracted with 4 M guanidinium chloride and 0.05 M Tris/HCl, pH 8.0, containing proteinase inhibitors as described \[[@B21]\]. The extract was centrifuged at 15000 ***g*** for 10 min to remove insoluble material. The protein concentration of each sample was determined using a BCA (bicinchoninic acid) protein assay kit (Thermo Fisher Scientific) according to the manufacturer\'s instructions. The CSPG fractions were precipitated with 70% ethanol containing 5% sodium acetate. The partially purified CSPG fraction was digested with chondroitinase ABC, and the digests were then derivatized with 2-AB and analysed by HPLC as previously described \[[@B22]\].

Gel-filtration chromatography of CS
-----------------------------------

To determine the chain length of CS, the purified CSPG fraction was subjected to reductive β-elimination using NaBH~4~/NaOH, and then analysed by gel-filtration chromatography on a column (10 × 300 mm) of Superdex 200 eluted with 0.2 M ammonium bicarbonate at a flow rate of 0.4 ml/min. Fractions were collected at 3 min intervals, lyophilized and digested with chondroitinase ABC. The digests were derivatized with 2-AB, and then analysed by HPLC on an amine-bound PA-03 column \[[@B22]\]. The amounts of the 2-AB derivatives of unsaturated disaccharides were calculated based on fluorescence intensity.

Quantitative real-time RT (reverse transcription)--PCR
------------------------------------------------------

Total RNA was extracted from articular cartilage using RNeasy Lipid Tissue Mini kit (Qiagen) according to the manufacturer\'s instructions. The cDNA was synthesized from \~1 μg of total RNA using Moloney-murine-leukaemia virus reverse transcriptase (Promega) and an oligo(dT)~20~-M4 adaptor primer (Takara). The primer sequences used were as follows: *CSGalNAcT1*, forward primer 5′-CCAATTTCAGAAACTTCACCTTCAT-3′ and reverse primer 5′-TGTTCAGCCTACAAGTGTTGAG-3′; *CSGalNAcT2*, forward primer 5′-TTAATATCATTGTGCCACTTGCG-3′ and reverse primer 5′-TAGAATAGACTTGACTTTAGATAGTCCTT-3′; *C4st-1* (chondroitin 4-sulfotransferase-1), forward primer 5′-ACCTCGTGGGCAAGTATGAG-3′ and reverse primer 5′-TCTGGAAGAACTCCGTGGTC-3′; *Fam20B* (family member 20B) \[[@B23]\], forward primer 5′-TTGTCTTTAAGCCTAAGCGGT-3′ and reverse primer 5′-GGCTTAACTTCTGTCCGCA-3′; and *G3pdh* (glyceraldehyde-3-phosphate dehydrogenase), forward primer 5′-CATCTGAGGGCCCACTG-3′ and reverse primer 5′-GAGGCCATGTAGGCCATGA-3′. Quantitative real-time RT--PCR was performed using a FastStart DNA Master plus SYBR Green I (Roche Diagnostics) in a LightCycler ST300 (Roche Diagnostics). The expression levels of *CSGalNAcT1, CSGalNAcT2*, *C4st-1* and *Fab20B* mRNA were normalized to that of the *G3pdh* transcript.

Western blot analysis with anti-CSGalNAcT1 antibody
---------------------------------------------------

The anti-CSGalNAcT1 antibody was generated against recombinant GST (glutathione transferase)--CSGalNAcT1 (amino acids 261--534). E18.5 cartilage and brain extracts (0.1 mg of total protein) were subjected to SDS/PAGE (10% gels), followed by immunoblot analysis.

Body length and weight
----------------------

Measurements were performed on adults from the dorsal tip of the nose to the dorsal base of the tail while mice were under anaesthesia. The body weight and body length measurements were based on data from seven male offspring from seven unique litters. Statistical analysis was performed using a Student\'s *t* test and the data are represented as the means±S.E.M. \**P*\<0.05.

Skeletal analysis
-----------------

Embryos were eviscerated under anaesthetic (isoflurane or pentobarbital) and fixed in 100% ethanol for 4 days. Toluidine Blue staining was performed in a solution of 80% ethanol, 20% acetic acid and 0.015% Toluidine Blue for 4 days at 37 °C. Specimens were rinsed and soaked in 100% ethanol for 3 days. Alizarin Red staining was then performed in a solution of 0.002% Alizarin Red and 1% KOH for 12 h at room temperature (25 °C). After rinsing with water, specimens were kept in 1% KOH solution until the skeletons become clearly visible. For storage, specimens were transferred sequentially into 50%, 80%, and finally 100% glycerol. Tibial length was determined by measuring the distance between the proximal and distal articular surfaces with a ruler under light microscopy.

Thickness of epiphyseal cartilage
---------------------------------

To compare the thickness of epiphyseal cartilage of proximal femurs, formalin-fixed and paraffin-embedded bones of the limbs from E18.5 and at 4 weeks of postnatal development were used. The tissue material was sliced into serial sections and stained with haematoxylin/eosin. An SZX16 microscope (Olympus) with a digital camera Axiocam HRc (Zeiss) was used to collect image data from the serial sections, and the thickness of the epiphyseal cartilage was calculated from the length of the longitudinal centre axis by Imaris (Zeiss) and ImageJ (National Institutes of Health). A double-blind histological comparison between the null and the wild-type mice was performed. A Mann--Whitney *U* test was used to analyse the data.

Tissue preparation for mouse specimens
--------------------------------------

Mice were anaesthesitized with diethyl ether and pentobarbital (Nembutal; Dinabot) and then perfused with 4% paraformaldehyde solution (pH 7.4) under anaethestia tibiae of E18.5 *CSGalNAcT1*^−/−^ fetuses were extracted, decalcified, and embedded in paraffin as previously described \[[@B24]\]. Immunostained sections of the mice were observed under a Nikon Eclipse E800 microscope, and light microscopic images were acquired with a digital camera (Nikon DXM1200C). For TEM (transmission electron microscope) observations, fixed specimens were decalcified, post-fixed with osmium tetroxide, dehydrated, and embedded in epoxy resin (Epon 812) as previously described \[[@B10]\]. Ultra-thin sections were obtained with an ultra microtome (Sorvall MT-5000) and stained with an aqueous solution of 1% tannic acid, 4% uranyl acetate and 2% lead citrate. These specimens were observed using a TEM (Hitachi H-7100) at 80 kV.

Immunostaining for type-II collagen and PCNA (proliferating cell nuclear antigen)
---------------------------------------------------------------------------------

Dewaxed paraffin sections were pre-treated for endogenous peroxidase inhibition with 0.3% H~2~O~2~ in PBS for 20 min and treated as described previously with a 0.5% hyaluronidase solution (type I-S, from bovine testis; Sigma) for 10 min \[[@B24]\]. They were subjected to blocking for non-specific binding with BSA/PBS (1% BSA in PBS) for 30 min at room temperature. Sections were then incubated with rabbit anti-type-II or type-X collagen (1:100; LSL) overnight at 4 °C followed by incubation with HRP (horseradish peroxidase)-conjugated anti-(rabbit Igs) (Chemicon International) overnight at 4 °C. Other sections were incubated with mouse monoclonal antibody against PCNA (Oncogene), followed by incubation with HRP-conjugated anti-(mouse IgG) (Chemicon). Visualization of the immune complex was performed with diaminobenzidine tetrahydrochloride. All sections were faintly counterstained with Methyl Green.

RESULTS
=======

To investigate the role of CS synthesis in skeletal development, we inactivated the *CSGalNAcT1* gene by targeted gene replacement in ES cells and subsequent gene knockout in transgenic mice. The DXD motif is present in most GalNAc/Gal transferases and is essential to the *in vitro* activity of these enzymes as the binding site for divalent metal cations such as Mn^2+^ \[[@B25]--[@B27]\]; therefore we focused on this motif in our gene targeting and gene knockout strategy. Since mouse CSGalNAcT1 has a DXD motif that is encoded in exon 7, we designed the targeting vector with exon 7 located between two loxP sites. Specifically, the neomycin-resistance cassette (*neo*-cassette) was inserted adjacent to exon 7 ([Figure 1](#F1){ref-type="fig"}A). After the *Cre* recombinase-dependent excision of the exonic sequences flanked by loxP sites, a frame shift occurs that should prevent the production of normal CSGalNAcT1 enzyme ([Figure 1](#F1){ref-type="fig"}A).

![*CSGalNAcT1*-null mice did not express the CSGalNAcT1 enzyme\
(**A**) Construct of the targeting vector for producing the *CSGalNAcT1*-null mice. The numbers represent the exon number (exon 1 is defined as the first exon of this gene where the transcription starts). RV, EcoRV site; S, ScaI site. (**B**) Immunoblot analysis using an anti-CSGalNAcT1 antibody to probe head homogenate from wild-type mice (lane 2), heterozygous (*CSGalNAcT1*^+/−^) mice (lane 3) and null mice (*CSGalNAcT1*^−/−^) at E18.5. Lane 1 shows the negative control (wild-type homogenate after absorption by the recombinant CSGalNAcT1 protein). Note that no reactivity was evident in the homogenate from null mice (lane 4). (**C**) RT--PCR analysis of genes encoding several enzymes involved in CS synthesis. The expression level is shown as a ratio of each gene to *G3pdh* for normalization. Fam20B is an enzyme that phosphorylates xylose \[[@B23]\]. Note that no other specific enzymes showed elevated expression to compensate for the loss of CSGalNAcT1 protein.](bic633i001){#F1}

The vector was introduced into the C57BL/6 ES cells, and chimaeric mice containing clonal recombinant ES cells were crossed with C57BL/6 mice. The complete null mice were obtained by mating the floxed mouse with a telencephalin-*Cre* mouse that expressed the *Cre*-recombinase in all cell types of early stage embryos ([Figure 1](#F1){ref-type="fig"}A) \[[@B19]\].

The CSGalNAcT1 protein and *CSGalNAcT1* mRNA was completely absent from *CSGalNAcT1*-null mice based on immunoblotting ([Figure 1](#F1){ref-type="fig"}B) and RT--PCR ([Figure 1](#F1){ref-type="fig"}C) analyses respectively. The *CSGalNAcT1*-null mice were viable and fertile. The protein and mRNA levels in heterozygous mice (*CSGalNAcT1*^+/−^) were decreased to 38% and 40% respectively of those in the wild-type controls ([Figures 1](#F1){ref-type="fig"}B and [1](#F1){ref-type="fig"}C). Other enzymes related to CS synthesis, including CSGalNAcT2, a paralogue of CSGalNAcT1, were not up-regulated in the *CSGalNAcT1*-null mice ([Figure 1](#F1){ref-type="fig"}C), indicating that no compensatory elevation in expression of related enzymes occurred.

The null mice were viable and fertile; however, we found a large number of abnormalities in the cartilages of these mice. CS production in the cartilage of heterozygous mice (64.4±5.3 nmol/mg of protein) was not reduced compared with that of wild-type mice (63.0±4.4 nmol/mg of protein); however, total CS content in *CSGalNAcT1*-null mice was less than half (31.0±3.0 nmol/mg of protein; *n*=6 of each; [Figure 2](#F2){ref-type="fig"}A) of that in the wild-type controls. Normally, CS appears metachromatically violet in Toluidine Blue-stained samples. On the basis of Toluidine Blue staining, the cartilage of wild-type controls was enriched with CS, and the metachromasia indicative of CS was not observed in the *CSGalNAcT1*-null mice ([Figure 2](#F2){ref-type="fig"}B). Consistent with observation of aggregated collagen fibres under electron microscopic observation, there were many speculate fibres in the *CSGalNAcT1*-null mice (see arrows in [Figure 1](#F1){ref-type="fig"}B; also see below and [Figure 5](#F5){ref-type="fig"}). CS in the null mice was compositionally similar to that in the control mice except for a reduction in the proportion of the non-sulfated disaccharide ([Figure 2](#F2){ref-type="fig"}A).

![CS production in cartilage is reduced in *CSGalNAcT1*-null mice\
(**A**) The total amount and disaccharide analysis of the cartilage in wild-type (Wt), heterozygous (+/−; *CSGalNAcT1*^+/−^) and null (−/−; *CSGalNAcT1*^−/−^) mice. Student\'s *t* test was performed to compare the disaccharide amount derived from CS in the null mice with that in the wild-type or the heterozygous mice. Results are shown as mean±S.E.M. \**P*\<0.05; \*\**P*\<0.01 (*n*=6). Δdi-0S, ΔHexAα1-3GalNAc; Δdi-4S, ΔHexAα1-3GalNAc(4S); Δdi-6S, HexAα1-3GalNAc(6S). (**B**) Toluidine Blue staining of the epiphyseal cartilage from E18.5 wild-type (*Wt*; left) and *CSGalNAcT1*-null (−/−) fetuses. Metachromasia of Toluidine Blue (purple colour) can be seen in the wild-type cartilage, whereas no metachromasia is discernible in the null mice cartilage. Note the reduced size of the epiphyseal cartilage in the null mice, compared with their wild-type counterpart (bidirectional arrows, upper panels). The extracellular spaces in the cartilage of null mice have many spicules (arrows, lower panels), whereas the intercellular regions from wild-type mice do not. *pro*, proliferative zone; *hyp*, hypertrophic zone. Scale bars: in upper panels, 200 μm; in lower panels, 50 μm. (**C**) Gel-filtration analysis of the length of CS sugar chains in the E18.5 cartilage in wild-type (●), heterozygous (*CSGalNAcT1*^+/−^; ○) and null (*CSGalNAcT1*^−/−^; ▲) mice. There are no significant differences in the total amount of CS loaded on to the gels among groups. Note that the second peak between fraction numbers 30 and 35 is present both in wild-type and heterozygous mice, but not in *CSGalNAcT1*-null mice, indicating that the size of the GAG chains of CS changed in *CSGalNAcT1*-null mice. Arrowheads indicate the size of the molecular-mass-marker standards \[mean molecular masses (K, kDa): 200, 65.5, 37.5 and 18.1 respectively; all from Sigma\]. The calibration of the Superdex 200 column was performed using a series of size-defined commercial dextran polysaccharides. The results shown represent one of three series of independent experiments, where the three series of experiments gave essentially identical results.](bic633i002){#F2}

Using gel filtration, we determined the size of the CS chains ([Figure 2](#F2){ref-type="fig"}C). Unexpectedly, the CS chains from the cartilage in *CSGalNAcT1*-null mice were not the same in size as those from cartilage of wild-type or heterozygous mice. Specifically, CS chains of different lengths in the developing cartilage were identified as individual peaks in samples from wild-type mice ([Figure 2](#F2){ref-type="fig"}C, closed circle). The longest CS chains were preserved in the null mice, but the amount of shorter chains was significantly reduced relative to the amount in wild-type animals ([Figure 2](#F2){ref-type="fig"}C).

The *CSGalNAcT1*-null mice had a slightly but significantly shorter mean body length and smaller mean body weight than the wild-type controls ([Figures 3A--3C](#F3){ref-type="fig"}); these differences were most likely due to the shorter limbs and axial skeleton of the null mice ([Figure 3](#F3){ref-type="fig"}D). In contrast, the skulls of the mutant mice were similar in circumference and body weight to those of the heterozygous and wild-type mice ([Figure 3](#F3){ref-type="fig"}D). The null mice had femurs that were 10% shorter than those of wild-type and heterozygous mice on E18.5 ([Figure 3](#F3){ref-type="fig"}E).

![*CSGalNAcT1*-null mice have reduced skeletal growth\
(**A** and **B**) The body weight (**A**) and the body length (**B**) in the wild-type (●) and *CSGalNAcT1*-null mice (○) during postnatal development. At 4 weeks after birth, the body mass and the body length of the null mice were slightly reduced compared with those of the wild-type.\**P*\<0.05 (Student\'s *t* test). (**C**) The fetal body (top panel) and skeleton (bottom panel) of wild-type (Wt), heterozygous (+/−) and null (−/−) mice. (**D**) Various bone segments of the fetal mice. Note that only forelimb bones of the null mice are shorter than those of wild-type mice. (**E**) Measurements of femur length. The femurs at E18.5 of the null mice are significantly shorter than those of wild-type and heterozygous mice (Student\'s *t* test; *P*\<0.00001). The number of the femurs measured for each genotype is shown in parentheses. The results are shown as means±S.E.M.](bic633i003){#F3}

The epiphyseal cartilage of the femur in the *CSGalNAcT1*-null mice was apparently thinner than that of wild-type mice at E18.5 ([Figure 4](#F4){ref-type="fig"}A). Type-II collagen staining also clearly showed thinning of the cartilage in the null mice ([Figure 4](#F4){ref-type="fig"}C). At 4 weeks of postnatal development, the growth plate in null mice was still smaller than that in the wild-type animals ([Figures 3](#F3){ref-type="fig"}B and [3](#F3){ref-type="fig"}D). In the null mice, the area of type-X collagen immunostaining, a marker of the hypertrophic zone in cartilage, was slightly smaller than that of wild-type animals at E18.5 and after 4 weeks of postnatal development ([Figures 4](#F4){ref-type="fig"}C and [4](#F4){ref-type="fig"}D). The cartilage thickness at E18.5 was 25% narrower in *CSGalNAcT1*-null mice than in wild-type animals ([Figure 3](#F3){ref-type="fig"}E). After 4 weeks of postnatal development, the cartilage of the null mice was still 15% thinner than that of the wild-type controls ([Figure 4](#F4){ref-type="fig"}E). Staining for the cell proliferation marker PCNA was similar in chondrocytes of wild-type and null mice (results not shown), indicating that cell proliferation is not impaired in *CSGalNAcT1*-null mice and is not the cause of the cartilage abnormalities in the mutant animals ([Figures 4](#F4){ref-type="fig"}C and [4](#F4){ref-type="fig"}D).

![The thickness of the growth plate is reduced in *CSGalNAcT1*-null mice\
(**A**) Histological views of the epiphyses of E18.5 wild-type (*Wt*) and *CSGalNAcT1*-null (−/−) mice. Upper panels: hind limbs (*f*, femur; *t*, tibia), middle panels: the femurs of these littermates; lower panels: higher magnification views of the middle panels focusing on the epiphyseal cartilage. Consistent with the decreased size of femurs and tibiae of the null mice, the femoral epiphyseal cartilage (*epi*) was reduced in size in null mice compared with that of their wild-type counterparts. Scale bar: upper panels, 1 mm; middle panels, 500 μm; lower panels, 300 μm. (**B**) Histological findings on the growth plates of 4-week-old wild-type (*Wt*) and null (−/−) mice. Upper and lower panels show lower and higher magnification respectively. The longitudinal length of the growth plates (*GP*) was shortened in the null mice (bidirectional arrows, lower panels). Scale bars: upper panels, 800 μm; lower panels, 200 μm. (**C** and **D**) Immunodetection of type-II (II; upper panels) and type-X (X; lower panels) collagen in the epiphyses of the wild-type (*Wt*) and null *(−/−)* E18.5 fetuses (**C**) and 4-week-old mice (**D**). In (**C**), the type-II collagen-positive area (brown) was seen throughout the epiphyses of both *Wt* and null mice, despite the finding that cartilage area of the null mice was reduced (upper panels). Even in (**D**), the reduced size of the type-II collagen reactive-growth plate in the null mice was observed. Judging from the hypertrophic zone marker type-X collagen immunostaining, cartilage from E18.5 (**C**) and four-week-old (**D**) animals had a reduced hypertrophic zone. Scale bars: (**C**), 300 μm; (**D**), 100 μm. (**E**) Quantitative measurement of the epiphyseal cartilage in area. Both E18.5 and 4-week-old (*4w*) femurs were collected. (Mann--Whitney *U* test; *P*\<0.05). The results are shown as means±S.E.M.](bic633i004){#F4}

The extracellular matrix of cartilage is composed of two major structural components: collagen fibres and PG aggregates \[[@B12]\]. We examined the ultrastructure and arrangement of the collagen fibres in *CSGalNAcT1*-null mice using electron microscopy. Type-II collagen fibres were abnormally aggregated in the proliferative and resting layers of the cartilage ([Figures 5A--5D](#F5){ref-type="fig"}). The fibres were thickened and convoluted in the cartilage substance ([Figure 5](#F5){ref-type="fig"}F). The aggregated collagen fibres appeared to be associated with the chondrocytes of the null mice ([Figure 5](#F5){ref-type="fig"}D), and this arrangement was not observed in wild-type tissue ([Figures 5](#F5){ref-type="fig"}A, [5](#F5){ref-type="fig"}C and [5](#F5){ref-type="fig"}E). These results indicate that CSGalNAcT1 is important in establishing and/or maintaining normal cartilage ultrastructure including the arrangement of collagen fibres and the CSPG matrix.

![Abnormal ultrastructure of the type-II collagen is frequently observed in cartilage and chondrocytes of *CSGalNAcT1*-null mice\
(**A**, **C** and **E**) Wild-type (*Wt*) mice; (**B**, **D** and **F**) *CSGalNAcT1*-null (−/−) mice; at E18.5. Micrographs (**A**) and (**B**) were obtained from the resting zone, and (**C**) and (**D**) from the proliferative zones. Note that many electron-dense extracellular fibrils (arrows) are seen connecting chondrocytes in the resting (**B**) and proliferative (**D**) zones of the epiphysis from null mice, whereas only a few such fibrils are observed in both zones (**A**; resting zone, and **C**; proliferative zone) of wild-type mice. At a higher magnification, the wild-type cartilage matrix had collagen fibrils that spread radially (**E**), whereas cartilage of the null mice had a fine meshwork of twisted cartilaginous fibrils (**F**). Ch, chondrocytes. Scale bars: (**A**)--(**D**), 10 μm; (**E**)--(**F**), 1 μm.](bic633i005){#F5}

DISCUSSION
==========

In the present study, we demonstrated that CSGalNAcT1 is one of the key enzymes for CS biosynthesis in skeletal and cartilage development *in vivo* by generating and analysing *CSGalNAcT1*-null mice. The specific substrates of CS-synthesizing glycosyltransferases, including CSGalNAcT1, are firmly established based on *in vitro* studies \[[@B9],[@B10],[@B14]\]; however, no previous report definitively addresses the *in vivo* physiological function of any enzyme involved in CS synthesis. In the present study, we make two observations in *CSGalNAcT1*-null mice: (i) abnormalities in CS biochemistry; and (ii) defects in cartilage development, suggesting that this enzyme is essential for normal cartilage development and normal CS synthesis. During the early stages of embryonic cartilage development, this enzyme was required for at least 50% of the total CS synthesis ([Figure 4](#F4){ref-type="fig"}A), indicating that other enzymes \[[@B5],[@B7]\] cannot fully compensate for the absence of this enzyme ([Figure 2](#F2){ref-type="fig"}B). CSGalNAcT1 is highly expressed in developing cartilage \[[@B14]\]; thus CSGalNAcT1 does have a non-redundant role in CS synthesis. The remaining 50% of CS synthesis in cartilage is probably dependent upon the activities of ChSy-1 (chondroitin synthase 1), ChSy-3 and ChPF (chondroitin polymerization factor) because they are expressed at high levels in this tissue, and any combinations of two of these enzymes can catalyse chondroitin polymerization in *in vitro* experiments \[[@B3],[@B9]\]. CSGalNAcT2 is much less abundant than CSGalNAcT1, ChSy-1, ChSy-3 or ChPF in cartilage; thus we believe that ChSy-1, ChSy-3 and ChPF contributed more significantly to CS synthesis than CSGalNAcT2 did in the *CSGalNAcT1*-null mice \[[@B14]\]; however, it is possible that CSGalNAcT2 was more active than ChSy-1, ChSy-3 or ChPF in CS chain elongation rather than initiation of CS synthesis in cartilage of *CSGalNAcT1*-null mice.

These results also indicate that CSGalNAcT1 may be required for the production of specific short-chain CS species ([Figures 2](#F2){ref-type="fig"}C and [2](#F2){ref-type="fig"}D). This is probably because CS GAG chains are synthesized differently depending upon the linkage position on the core protein, aggrecan. Other previous *in vitro* studies have demonstrated that CSGalNAcT1 and other CS-synthesizing enzymes have complex specificities, and these enzymes are thought to recognize the complicated three-dimensional structure of the sugar--core protein linkage to produce CS GAG chains *in vivo* \[[@B5],[@B9]\]. However, it is also possible that the number of CS chains is determined by the level of initiating CSGalNAcT enzymes in the wild-type mice, but that chain length may be limited, to some extent, by availability of sugar precursors and/or elongating enzyme, leading to some different-sized chains in *CSGalNAcT1*-null mice. Further studies using these mice are needed to clarify the exact *in vivo* mechanisms that results in the absence of shorter CS chains in *CSGalNAcT1*-null mice.

The exact reason for the delay in cartilage development in the *CSGalNAcT1*-null mice is unknown \[[@B28]\]; however, it has been suggested that Indian Hedgehog and FGF (fibroblast growth factor), key signal molecules operating in early growth plate development, interact with CS \[[@B29]\]. Thus it is likely that the reduction of CS could affect normal chondrogenesis. In addition, type II collagen fibres in the cartilage of *CSGalNAcT1*-null mice also showed abnormal aggregation, probably due to a reduction in CS ([Figure 5](#F5){ref-type="fig"}), indicating that this enzyme also affects the ultrastructure of cartilage during development. Since the network of type-II collagen fibres outlining the frame of the cartilage is filled with the CSPG gel, it is likely that electrostatic repulsion by negative charges derived from the large amount of CS in the wild-type animals prevents the collagen fibres from aggregating abnormally.

Many hereditary syndromes and idiopathic short stature patients are characterized by abnormal cartilage development, including those with PG defects \[[@B30]\]. Some of the hereditary syndromes and cases of idiopathic short stature might involve defects in CS synthesis and, more specifically, genetic errors in human *CSGalNAcT1*. We hope that our present study and the novel genetic model, the *CSGalNAcT1*-null mice, will contribute to the clinical investigations of these diseases.

AUTHOR CONTRIBUTION
===================

Yumi Watanabe, Susumu Higa Onaga, Michiko Sato, Mika Tsujita, Manabu Abe, Rie Natsume, Ayumi Hasegawa, Minesuke Yokoyama and Kenji Sakimura produced *CSGalNAcT1*-null mice ([Figure 1](#F1){ref-type="fig"}A), and Kosei Takeuchi performed the experiments and analysed the results shown in [Figures 1](#F1){ref-type="fig"}(B), [3](#F3){ref-type="fig"}(A), [3](#F3){ref-type="fig"}(B) and [4](#F4){ref-type="fig"}(E). Minqi Li and Norio Amizuka performed the experiments shown in [Figures 2](#F2){ref-type="fig"}(B), [4(A)--4(D)](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}. Mika Saeki, Tomomi Izumikawa and Hiroshi Kitagawa undertook the experiments shown in [Figures 1](#F1){ref-type="fig"}(C), [2](#F2){ref-type="fig"}(A) and [2](#F2){ref-type="fig"}(C). Tatsuya Furuichi and Shiro Ikegawa performed the experiments shown in [Figures 3(C)--3(E)](#F3){ref-type="fig"}. Kenji Sakimura, Norio Amizuka, Shiro Ikegawa, Hiroshi Kitagawa, and Michihiro Igarashi designed the experiments. Michihiro Igarashi conceived the ideas and wrote the paper.

ACKNOWLEDGEMENTS
================

We thank the members of the Department of Animal Resources (Brain Research Institute, Niigata University, Niigata, Japan) for efficient production of the targeted mice.

FUNDING
=======

This work was supported in part by the MEXT (Ministry of Education, Culture, Sports, Science and Technology) of Japan (KAKENHI) \[grant numbers 17023019, 22240040 (to M.I.), 20570187 (to K.T.), 21380025 (to H.K), 21390488 (to N.A.), 21249080 (to S.I.), 21300118 (to K.S.)\], the Naito Foundation (to H.K.), Research and Development Program for New Bio-industry Initiatives (to K.T.), and Niigata University (to M.I., Y.W. and S.H.O.). The production of the *CSGalNAcT1*-null mice was supported by TOGONO gene targeting support.

[^1]: ^1^These three authors contributed equally.

[^2]: ^2^Present address: Laboratory Animal Facility, Research Center for Medical Sciences, Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Kobe 658-8558, Japan.
